Results 31 to 40 of about 18,181 (226)

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars

open access: yesТерапевтический архив, 2021
Aim. To define the frequency of adverse events and loss of the response in patients with ulcerative colitis (UC) and Crohns disease (CD), treated with original medicine infliximab (IFX) Remicaide and its biosimilars. Materials and methods. We included
O. V. Knyazev   +7 more
doaj   +1 more source

Key drivers for market penetration of biosimilars in Europe

open access: yesJournal of Market Access & Health Policy, 2017
Background & Objectives: Potential drivers and barriers of biosimilar uptake were mainly analysed through qualitative approaches. The study objective was to conduct a quantitative analysis and identify drivers of biosimilar uptake of all available ...
Cécile Rémuzat   +5 more
doaj   +1 more source

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease. [PDF]

open access: yesJPGN Rep
Abstract Objectives Adalimumab biosimilars are as safe and effective compared to the originator. Adult patients with inflammatory bowel disease (IBD) who switched to a biosimilar have comparable outcomes, but pediatric data are limited. This study evaluates clinical outcomes of children and young adults with IBD following a nonmedical, insurance‐driven
Himelstein D   +5 more
europepmc   +2 more sources

Biosimilar: what it is not [PDF]

open access: yesBritish Journal of Clinical Pharmacology, 2015
A biosimilar is a high quality biological medicine shown to be in essence the same as an original product. The European Medicines Agency (EMA) paved the way in the regulatory arena by creating a safeguarding framework for the development of biosimilars.
openaire   +2 more sources

Imbalanced machine learning classification models for removal biosimilar drugs and increased activity in patients with rheumatic diseases.

open access: yesPLoS ONE, 2023
ObjectivePredict long-term disease worsening and the removal of biosimilar medication in patients with rheumatic diseases.MethodologyObservational, retrospective descriptive study.
David Castro Corredor   +1 more
doaj   +1 more source

Biosimilar Drugs for Therapy of Immune-Mediated Diseases

open access: yes, 2018
In recent years, biological therapy has been widely used for the treatment of immunemediated diseases in rheumatology, hematology, gastroenterology, etc.
Tsvetelina Velikova
core   +1 more source

Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice

open access: yesPharmacology Research & Perspectives, 2020
Recently, biosimilar erythropoietin stimulating agents become available in Kazakhstan. Important properties of the biosimilar such as dose equivalency to the original medicine (originator) and the ability to maintain hemoglobin target levels remain ...
Abduzhappar Gaipov   +7 more
doaj   +1 more source

Science of Biosimilars [PDF]

open access: yesJournal of Oncology Practice, 2017
Biosimilar therapeutic proteins in oncology offer the potential to decrease costs while providing safety and efficacy profiles consistent with their respective reference or originator products. Biosimilars have a number of important differences from generic small-molecule drugs, including manufacturing processes that are unique from their reference ...
openaire   +2 more sources

Biosimilars – terms of use [PDF]

open access: yesCurrent Medical Research and Opinion, 2015
The impending expiry of the patent on a number of leading biologic drugs has led to a surge in the development of 'biosimilar' or 'follow-on' products. However, in contrast to generic small-molecule medicines, biosimilars are not identical to their reference products.
Declerck, Paul   +2 more
openaire   +4 more sources

Biosimilar infliximab introduction into the gastro-enterology care pathway in a large acute Irish teaching hospital: a story behind the evidence [PDF]

open access: yes, 2018
Background and aim: Biosimilar medicines are not considered exact replicas of originator biological medicines. As a result, prescribers can be hesitant to introduce such medicines into the clinical setting until evidence surfaces confirming their safety ...
O\u27Brien, Gary L.   +14 more
core   +1 more source

Home - About - Disclaimer - Privacy